Results 31 to 40 of about 899,405 (297)

Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. [PDF]

, 2017
BACKGROUND: Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to
Abraham, Assandri, Assassi, Auluck, Bacher, Baron, Baron, Bodukam, Cavazzana, Chizzolini, Chizzolini, Ciechomska, Clark, Cohen, Colina, Crowell, Denton, Denton, Derk, Derynck, Emmanuel, Frech, Fynne, Gabrielli, Goldblatt, Gregersen, Gu, Hartleb, Heyt, Hinz, Hu, Hudson, Hung, Ingraham, Jimenez, Johnson, Jung, Kaburaki, Kaneko, Khanna, Khanna, Koh, Krause, Kumar, Luciano, Malandrini, Manetti, Manetti, Manetti, Marie, Marie, Marie, Marie, Marie, Matucci-Cerinic, Maurer, Miao, Milette, Murray-Lyon, Nagaraja, O'Reilly, O'Reilly, Omair, Parker, Parodi, Pattanaik, Peng, Piasecki, Poelman, Radic, Raja, Raja, Raja, Rajapakse, Reynolds, Richard, Richardson, Rigamonti, Riviere, Roulis, Russell, Sakkas, Savarino, Savarino, Shawis, Singh, Singh, Sjogren, Skare, Solis-Herruzo, Spiegel, Steen, Stern, Stumpf, Thonhofer, Thoua, Trezza, Trojanowska, Valenzuela, Varga, Veale, Vischio, Watson, Wipff, Wynn, Zheng   +105 more
core   +2 more sources

Thoracic duct fistula and renal transplantation [PDF]

, 1979
Thoracic duct drainage (TDD) was established for 21-115 days in 40 kidney recipients with an average removal per patient day of 4.7 1 lymph and 1.88 billion cells. Cellular and humoral immunity were depressed. TDD and immunosuppressive drugs were started
Franks, JJ, Halgrimson, CG, Iwaki, Y, Koep, LJ, McCalmon, RT, Schröter, GP, Starzl, TE, Subryan, V, Terasaki, PI, Weil, R   +9 more
core   +2 more sources

Successful treatment of hemorrhagic bullous Henoch‐Schonlein purpura with intravenous immunoglobulins

Pediatric dermatology, 2019
Henoch‐Schonlein purpura (HSP) is the most common systemic vasculitis in childhood. There is no consensus about the management for isolated cutaneous manifestations in HSP.
A. Mauro, Salvatore Mauro, R. Rega, L. Martemucci, R. Sottile   +4 more
semanticscholar   +1 more source

Continuous increase of immunoglobulin therapy in Iceland

Clinical Immunology Communications, 2022
Background: The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this ...
Valgeir Steinn Runólfsson, Björn Rúnar Lúdvíksson, Rannveig Einarsdóttir, Þórunn Óskarsdóttir, Valtýr Thors, Ásgeir Haraldsson   +5 more
doaj   +1 more source

Adjuvant treatment of severe varicella pneumonia with intravenous varicella zoster virus-specific immunoglobulins

International Journal of Infectious Diseases, 2019
Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive ...
Davide Mangioni, Giacomo Grasselli, Chiara Abbruzzese, Antonio Muscatello, Andrea Gori, Alessandra Bandera   +5 more
doaj   +1 more source

Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Few studies have addressed whether there are differences in clinical efficacy between intravenous methylprednisolone (methyl-Pd) and intravenous immunoglobulin (IVIg) use.
Chul Hee Kim, Yoon Seok Choi, Ji Young Moon, Duck Yong Kim, So Yeon Lee, Hyo Jin Lee, Hwan Jung Yun, Samyong Kim, Deog Yeon Jo, Ik Chan Song   +9 more
doaj   +1 more source

High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats

Journal of Neuroinflammation, 2018
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe adverse effect in patients receiving antitumor agents, and no effective treatment is available. Although the mechanisms responsible for the development of CIPN are poorly understood, recent
C. Meregalli, I. Marjanović, C. Scali, L. Monza, Nadia Spinoni, C. Galliani, R. Brivio, A. Chiorazzi, E. Ballarini, V. Rodriguez-Menendez, V. Carozzi, P. Alberti, G. Fumagalli, E. Pozzi, A. Canta, M. Quartu, C. Briani, N. Oggioni, P. Marmiroli, G. Cavaletti   +19 more
semanticscholar   +1 more source

INTRAVENOUS IMMUNOGLOBULIN APPLICATION IN CLINICAL PRACTICE

Педиатрическая фармакология, 2013
The article gives data on the structure and function of immunoglobulins. Given the multitude of mechanisms of their action, indications to their use are constantly expanding.
T. V. Latysheva, E. A. Latysheva
doaj   +1 more source

Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies [PDF]

, 2014
During recent years, an increasing number of neuromuscular diseases have been recognized either to be caused primarily by autoimmune mechanisms, or to have important autoimmune components.
Oliveira, Acary Souza Bulle, Pinto, Wladimir Bocca Vieira de Rezende, Souza, Paulo Victor Sgobbi de   +2 more
core   +3 more sources

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders

Therapeutic Advances in Neurological Disorders, 2015
Objective: Intravenous immunoglobulin administration has long been used in the treatment of autoimmune neuromuscular disorders. Immunoglobulins may be administered by intramuscular, intravenous or subcutaneous routes.
Min-Suk Yoon, Ralf Gold, Antonios Kerasnoudis   +2 more
doaj   +1 more source